Uncategorized
VIVID, VISTA trials: Aflibercept superior to laser treatment for DME
NEW ORLEANS — Parallel studies testing separate regimens of aflibercept injections against laser photocoagulation found both drug regimens to work better than laser photocoagulation in patients with diabetic macular edema.Reporting the primary results at 1 year of the VIVID and VISTA trials, Diana V. Do, MD, told colleagues at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting, “Eyes that were randomized to either dosing regimen of aflibercept had superior visual acuity outcomes compared to laser-treated eyes.”